Evidence map›Paper›PMID 42089826›Full record

ArticleAntimicrobial agents and chemotherapy2026

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant

Mikaela M Walker, Jason A Roberts, Yixuan Li, Saiyuri Naicker, Steven C Wallis, Jenny L Ordonez, Hayoung Won, Brian M Forde, Fekade B Sime

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mikaela M WalkerUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.
Jason A RobertsUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0001-6218-435X
Yixuan LiUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.
Saiyuri NaickerUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0003-4822-0558
Steven C WallisUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-2392-9854
Jenny L OrdonezUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.
Hayoung WonUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-9248-5134
Brian M FordeUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0002-2264-4785
Fekade B SimeUQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia.ORCID 0000-0003-4061-2063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenems, often regarded as the last line of defense in treatment of urinary tract infections and urosepsis caused by

Indexed as

AmikacinAnti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeEscherichia colibeta-LactamasesCarbapenemsDrug CombinationsDrug Resistance, Multiple, BacterialDrug Therapy, CombinationEscherichia coli InfectionsHumansMicrobial Sensitivity TestsThird Generation CephalosporinsAmikacinAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-LactamasesCarbapenemsCeftazidimeDrug CombinationsThird Generation Cephalosporinsavibactamcarbapenem-sparingceftazidimesynergy

Identifiers

PMID42089826
PMCPMC13231872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.